By far, the two most common prostate diseases are prostatitis and benign hyperplasia (BPH). Prostatitis may be complicated by BPH or accompanied by periodic exacerbations. Drug therapy is an important component of the overall treatment of prostate diseases. In addition, treatment often ends in failure due to improper treatment, missed medication, and when the condition is in remission, the disease is ignored.
Thus, 20-30% of patients are not satisfied with treatment, do not feel a reduction in urinary disorder symptoms and improve quality of life. Most likely, this is due to misjudgment of lower urinary tract function in men with BPH and, therefore, inappropriate choice of treatment.
As you know, prostatitis is acute and chronic (CP), caused by bacteria and bacteria.
Prostatitis in %
- acute bacterial prostatitis - 5-10%;
- chronic bacterial prostatitis - 6-10%;
- chronic bacterial prostatitis - 80–90%, including prostatitis - 20-30%.
The most common is chronic bacterial prostatitis, which must be controlled and prevented in a timely manner with and without BPH.
The main drugs to treat BPH and chronic prostatitis:
- 5a-reductase inhibitors (Finasteride, dutasteride);
- a-blocker (doxazosin, tamsulosin);
- phytotherapy (sabal palm extract);
- antibiotics;
- amino acid complex;
- animal organ extracts (prostate extract);
- insect repellent (product derived from insects).
At the same time, 13-30% of the effect from the use of blockers does not occur within 3 months of treatment - no further treatment with drugs of this class is recommended.
When prescribing Finasteride, doctors need to be prepared for the most significant side effects of the drug: impotence, decreased libido, decreased ejaculation that can lead to patients quitting on their own.
Treatment of BPH and prostatitis is an important, unresolved urological problem.
Frequent episodes of CP in the absence of an indication for prostatectomy force doctors to use additional methods of drug treatment. Usually, the presence of CP simultaneously exacerbates the course of BPH, because 80% of the inflammation is in benign prostatic hyperplasia.
Modern medicine presents us with new opportunities to treat CP and BPH and prevent exacerbations.